https://www.selleckchem.com/products/cpi-444.html
The paravalvular leak was detected in 52.1% ViV-TAVR patients compared with 0% among rSAVR patients ( 0.001). ViV-TAVR can be a safe and feasible alternative treatment option in patients with degenerated aortic valve bioprosthesis. The choice of treatment should include the patient's individual characteristics considering ViV-TAVR as a standard of care. ViV-TAVR can be a safe and feasible alternative treatment option in patients with degenerated aortic valve bioprosthesis. The choice of treatment should include the patient's ind
Like
Comment
Share
